WO2004064751A3 - Nanoparticle based stabilization of ir fluorescent dyes - Google Patents

Nanoparticle based stabilization of ir fluorescent dyes Download PDF

Info

Publication number
WO2004064751A3
WO2004064751A3 PCT/US2004/001472 US2004001472W WO2004064751A3 WO 2004064751 A3 WO2004064751 A3 WO 2004064751A3 US 2004001472 W US2004001472 W US 2004001472W WO 2004064751 A3 WO2004064751 A3 WO 2004064751A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
nanoparticle
fluorescent dyes
dyes
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/001472
Other languages
French (fr)
Other versions
WO2004064751A2 (en
Inventor
Mostafa Sadoqi
Jun Shao
Vishal Saxena
Sanil Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ST JOHNS UNIVERSITY NEW YORK
Original Assignee
ST JOHNS UNIVERSITY NEW YORK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ST JOHNS UNIVERSITY NEW YORK filed Critical ST JOHNS UNIVERSITY NEW YORK
Priority to US10/542,185 priority Critical patent/US20070148074A1/en
Priority to EP04702592A priority patent/EP1583473A2/en
Priority to CA002516116A priority patent/CA2516116A1/en
Publication of WO2004064751A2 publication Critical patent/WO2004064751A2/en
Publication of WO2004064751A3 publication Critical patent/WO2004064751A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention relates to a highly effective nanoparticle system for stabilizing near-infrared (near-IR) fluorescent dyes such as indocyanine (ICG) in order to enhance the dye's utility for biomedical application. This invention further relates to nanoparticles comprised of biodegradable polymer materials such as poly(dl-lactide-co-glycolide)(PLGA). The invention also relates to methods of preparing the nanoparticle-entrapped dyes, as well as methods for using them in bioimaging, diagnosis, and treatment of disease. The present invention also relates to compositions and kits comprising nanoparticle-entrapped dyes.
PCT/US2004/001472 2003-01-16 2004-01-15 Nanoparticle based stabilization of ir fluorescent dyes Ceased WO2004064751A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/542,185 US20070148074A1 (en) 2003-01-16 2004-01-15 Nanoparticle based stabilization of ir fluorescent dyes
EP04702592A EP1583473A2 (en) 2003-01-16 2004-01-15 Nanoparticle based stabilization of ir fluorescent dyes
CA002516116A CA2516116A1 (en) 2003-01-16 2004-01-15 Nanoparticle based stabilization of ir fluorescent dyes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44065803P 2003-01-16 2003-01-16
US60/440,658 2003-01-16

Publications (2)

Publication Number Publication Date
WO2004064751A2 WO2004064751A2 (en) 2004-08-05
WO2004064751A3 true WO2004064751A3 (en) 2005-01-06

Family

ID=32771845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/001472 Ceased WO2004064751A2 (en) 2003-01-16 2004-01-15 Nanoparticle based stabilization of ir fluorescent dyes

Country Status (4)

Country Link
US (1) US20070148074A1 (en)
EP (1) EP1583473A2 (en)
CA (1) CA2516116A1 (en)
WO (1) WO2004064751A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE406462T1 (en) * 2004-08-18 2008-09-15 Hoffmann La Roche METHOD FOR MEASURING NUCLEIC ACID AMPLIFICATION IN REAL TIME INCLUDING THE POSITIONING OF A REACTION VESSEL RELATIVE TO A DETECTION UNIT
WO2006079091A1 (en) * 2005-01-24 2006-07-27 Mallinckrodt Inc. Methods of providing long-term stability to biocompatible optical dyes and bodily fluids
JP4982839B2 (en) * 2005-06-22 2012-07-25 国立大学法人京都大学 Vitreous visualization agent
US20090280064A1 (en) * 2005-06-24 2009-11-12 Rao Papineni Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans
US7470731B2 (en) 2005-06-24 2008-12-30 Pitney Bowes Inc. Fluorescent ink
EP1760467A1 (en) * 2005-09-02 2007-03-07 Schering AG Optically fluorescent nanoparticles
WO2007062207A2 (en) * 2005-11-23 2007-05-31 Schering Corporation Methods for quantifying polymer attachment to a particle
DE102006026203A1 (en) * 2006-05-31 2007-12-06 Carl Zeiss Microimaging Gmbh Method for spatially high-resolution imaging
WO2008005514A2 (en) 2006-07-06 2008-01-10 The Trustees Of Columbia University In The City Of New York Polychromatic, diversely-sized particles for angiography
US8337809B2 (en) 2006-09-11 2012-12-25 William Marsh Rice University Charge-assembled capsules for phototherapy
KR100925690B1 (en) * 2007-09-10 2009-11-10 한국생명공학연구원 Polymer particles containing near-infrared fluorescent die and manufacturing method thereof
EP2036577A1 (en) 2007-09-14 2009-03-18 mivenion GmbH Diagnostic materials for optical image-forming investigation based on nanoparticulate formulations
US20110275686A1 (en) 2009-12-11 2011-11-10 Biolitec, Inc. Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)
US20130108552A1 (en) * 2010-03-01 2013-05-02 University Of Florida Research Foundation Inc. Near-ir indocyanine green doped multimodal silica nanoparticles and methods for making the same
US8758778B2 (en) 2010-09-16 2014-06-24 The Regents Of The University Of California Polymeric nano-carriers with a linear dual response mechanism and uses thereof
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
CA2830600C (en) 2011-03-23 2021-07-27 Tomokazu AMANO Compositions and methods for enhancing the pluripotency of stem cells
JP6129155B2 (en) 2011-04-12 2017-05-17 ライジェル ファーマシューティカルズ， インコーポレイテッド Methods for suppressing allograft rejection
WO2012158561A1 (en) 2011-05-13 2012-11-22 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Use of zscan4 and zscan4-dependent genes for direct reprogramming of somatic cells
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
CN104768538A (en) 2012-08-28 2015-07-08 加利福尼亚大学董事会 Polymeric nanocarriers with light-triggered release mechanism
EP2968392B1 (en) 2013-03-15 2020-08-05 Elixirgen Therapeutics, Inc. Methods of using zscan4 for rejuvenating human cells
CA2907915C (en) 2013-04-03 2023-03-07 Allertein Therapeutics, Llc Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
US9915757B1 (en) 2013-06-24 2018-03-13 The Research Foundation For The State University Of New York Increased thermal stabilization of optical absorbers
WO2015061361A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
EP3119415A4 (en) 2014-03-07 2017-11-29 The Arizona Board of Regents on behalf of the University of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
US10758520B1 (en) 2015-05-20 2020-09-01 University Of South Florida Glutathione-coated nanoparticles for delivery of MKT-077 across the blood-brain barrier
CN105267965B (en) * 2015-10-15 2018-08-21 苏州杰纳生物科技有限公司 A kind of poly (lactic acid-glycolic acid) compound and preparation method thereof
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
EP3775236A1 (en) 2018-04-12 2021-02-17 Krystal Biotech, LLC Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
CN108619515A (en) * 2018-07-10 2018-10-09 天津工业大学 A kind of preparation and application of the tungsten oxide and indocyanine green microballoon of PLGA claddings
AU2019346549B2 (en) 2018-09-24 2024-09-12 Krystal Biotech, Inc. Compositions and methods for the treatment of Netherton Syndrome
EP3856914A1 (en) 2018-09-26 2021-08-04 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
EP3860635A4 (en) 2018-10-04 2022-07-06 Rutgers, The State University of New Jersey METHODS FOR REDUCING CYTOKINE TYPE 2-MEDIATED INFLAMMATION USING NEUROMEDIN PEPTIDES
CN109799216B (en) * 2018-12-29 2021-11-12 佛山科学技术学院 Fluorescence OCT dual-mode imaging method and device based on green nano indocyanine
CN113454105A (en) 2019-02-08 2021-09-28 克里斯托生物技术股份有限公司 Compositions and methods for delivering CFTR polypeptides
JP2022524516A (en) * 2019-03-08 2022-05-06 ノース カロライナ ステート ユニバーシティ Photothermia that promotes tumor infiltration and antitumor activity of CART T cells
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
US20230118087A1 (en) 2019-09-03 2023-04-20 Krystal Biotech, Inc. Compositions and methods for the treatment of congenital ichthyoses
EP4077688A1 (en) 2019-12-20 2022-10-26 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
WO2021225781A2 (en) 2020-05-07 2021-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
IL307350A (en) 2021-04-02 2023-11-01 Krystal Biotech Inc Viral vectors for cancer therapy
CN113730576B (en) * 2021-08-31 2023-03-28 佛山市第一人民医院（中山大学附属佛山医院） Application of nano photo-thermal material in preparation of laser depilation drug
JP2026508358A (en) 2023-03-02 2026-03-10 クリスタル バイオテック インコーポレイテッド Interleukin-2 and interleukin-12 for cancer treatment
EP4695408A1 (en) 2023-04-13 2026-02-18 Krystal Biotech, Inc. Methods and compositions for the treatment of conditions involving the eye
WO2026094007A1 (en) 2024-11-01 2026-05-07 Krystal Biotech, Inc. Compositions and methods for the treatment of atpase disorders or diseases of the skin
CN119700706B (en) * 2024-11-26 2026-05-05 郑州大学 Near-infrared responsive antibacterial nanomaterial, its preparation method and application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214560B1 (en) * 1996-04-25 2001-04-10 Genicon Sciences Corporation Analyte assay using particulate labels
US6268222B1 (en) * 1998-01-22 2001-07-31 Luminex Corporation Microparticles attached to nanoparticles labeled with flourescent dye
US6424857B1 (en) * 1997-06-16 2002-07-23 Amersham Health As Use of acousto-optical and sonoluminescene contrast agents
US6471968B1 (en) * 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
US6602932B2 (en) * 1999-12-15 2003-08-05 North Carolina State University Nanoparticle composites and nanocapsules for guest encapsulation and methods for synthesizing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267235A (en) * 1979-03-19 1981-05-12 California Institute Of Technology Polyglutaraldehyde microspheres
US5073498A (en) * 1984-12-24 1991-12-17 Caribbean Microparticles Corporation Fluorescent alignment microbeads with broad excitation and emission spectra and its use
US5395688A (en) * 1987-10-26 1995-03-07 Baxter Diagnostics Inc. Magnetically responsive fluorescent polymer particles
US5437274A (en) * 1993-02-25 1995-08-01 Gholam A. Peyman Method of visualizing submicron-size vesicles and particles in blood circulation
US6592847B1 (en) * 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
US6695870B2 (en) * 2002-02-25 2004-02-24 Nanocomp, L.L.C. Process for treating disease
US6964747B2 (en) * 2003-01-21 2005-11-15 Bioarray Solutions, Ltd. Production of dyed polymer microparticles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214560B1 (en) * 1996-04-25 2001-04-10 Genicon Sciences Corporation Analyte assay using particulate labels
US6424857B1 (en) * 1997-06-16 2002-07-23 Amersham Health As Use of acousto-optical and sonoluminescene contrast agents
US6268222B1 (en) * 1998-01-22 2001-07-31 Luminex Corporation Microparticles attached to nanoparticles labeled with flourescent dye
US6602932B2 (en) * 1999-12-15 2003-08-05 North Carolina State University Nanoparticle composites and nanocapsules for guest encapsulation and methods for synthesizing same
US6471968B1 (en) * 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform

Also Published As

Publication number Publication date
WO2004064751A2 (en) 2004-08-05
EP1583473A2 (en) 2005-10-12
US20070148074A1 (en) 2007-06-28
CA2516116A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
WO2000071162A3 (en) Cyanine and indocyanine dye bioconjugates for biomedical applications
AU2020288624B2 (en) Silk-based products, formulations, and methods of use
Lee et al. Near‐infrared mesoporous silica nanoparticles for optical imaging: characterization and in vivo biodistribution
Park et al. Photoluminescent and biodegradable porous silicon nanoparticles for biomedical imaging
WO2006010083A3 (en) Biodegradable nanoparticles
WO2003087165A3 (en) Biocompatible materials and probes
WO2005089813A3 (en) Receptor-avid exogenous optical contrast and therapeutic agents
US12152182B2 (en) Polymer nanoparticles for afterglow molecular imaging
WO2005089106A3 (en) Degradable nanoparticles
EP2530157A3 (en) Oligomeric compounds and compositions for use in modulation of small non-coding rnas
CN113876600B (en) Detection and treatment of caries and microcavities with nanoparticles
WO2005055736A8 (en) Compositions of marine botanicals to provide nutrition to aging and environmentally damaged skin
EP2609935A1 (en) Switching fluorescent nanoparticle probe and fluorescent particle imaging method using same
BR0215238A (en) Use of synthetic inorganic nanoparticles as vehicles for ophthalmic and optical drugs
CN103509552B (en) Functional near-infrared fluorescence nanoparticles and preparation and application thereof
EP1203141A1 (en) Linkage of agents to tissue
KR20080092706A (en) Polymer nanoparticles containing UV blocking material and its manufacturing method
EP1790728A3 (en) Imaging, diagnosis and treatment of disease
WO2005000218A3 (en) Macrocyclic cyanine and indocyanine bioconjugates provide improved biomedical applications
EP1250095A4 (en) VERSATILE HYDROPHILIC DYES
CN107652967B (en) Auto-fluorescent polyacrylamide nano particle and preparation method and application thereof
Albers et al. Self‐Assembled (Aza) BODIPY Dyes for Biomedical in Vivo Imaging
CN110542671B (en) Organic two-photon fluorescent probe, preparation and application thereof
WO2007077531A8 (en) Quinaldine based semisquaraines and squaraine dyes, process for preparation thereof and use thereof
KR20200006748A (en) Nanoparticles comprising near infrared absorption dye, methods for manufacturing thereof, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004702592

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2516116

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20048054256

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004702592

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007148074

Country of ref document: US

Ref document number: 10542185

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10542185

Country of ref document: US